635 related articles for article (PubMed ID: 26945402)
1. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.
Wang Y; Chen Q; Wang N; Chen H; Lyu Q; Kuang Y
Medicine (Baltimore); 2016 Mar; 95(9):e2939. PubMed ID: 26945402
[TBL] [Abstract][Full Text] [Related]
2. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
[TBL] [Abstract][Full Text] [Related]
3. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
Xiao ZN; Peng JL; Yang J; Xu WM
Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
[TBL] [Abstract][Full Text] [Related]
4. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial.
Dong J; Wang Y; Chai WR; Hong QQ; Wang NL; Sun LH; Long H; Wang L; Tian H; Lyu QF; Lu XF; Chen QJ; Kuang YP
BJOG; 2017 Jun; 124(7):1048-1055. PubMed ID: 28276192
[TBL] [Abstract][Full Text] [Related]
5. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
Kuang Y; Chen Q; Fu Y; Wang Y; Hong Q; Lyu Q; Ai A; Shoham Z
Fertil Steril; 2015 Jul; 104(1):62-70.e3. PubMed ID: 25956370
[TBL] [Abstract][Full Text] [Related]
6. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments.
Zhu X; Ye H; Fu Y
Medicine (Baltimore); 2016 Jul; 95(28):e4193. PubMed ID: 27428219
[TBL] [Abstract][Full Text] [Related]
7. Elevated basal luteinizing hormone does not impair the outcome of human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles.
Sun L; Ye J; Wang Y; Chen Q; Cai R; Fu Y; Tian H; Lyu Q; Lu X; Kuang Y
Sci Rep; 2018 Sep; 8(1):13835. PubMed ID: 30217999
[TBL] [Abstract][Full Text] [Related]
8. Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study.
Huang J; Xie Q; Lin J; Lu X; Zhu J; Gao H; Cai R; Kuang Y
Drug Des Devel Ther; 2019; 13():4461-4470. PubMed ID: 32099323
[TBL] [Abstract][Full Text] [Related]
9. Clomiphene citrate is associated with favorable cycle characteristics but impaired outcomes of obese women with polycystic ovarian syndrome undergoing ovarian stimulation for in vitro fertilization.
Jiang S; Kuang Y
Medicine (Baltimore); 2017 Aug; 96(32):e7540. PubMed ID: 28796038
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Different Progestins in Women With Advanced Endometriosis Undergoing Controlled Ovarian Hyperstimulation for
Guo H; Li J; Shen X; Cong Y; Wang Y; Wu L; Li B; Gao H; Ma M; Zhang W; Mao X; Fu Y; Lyu Q; Chai W; Kuang Y
Front Endocrinol (Lausanne); 2020; 11():129. PubMed ID: 32265834
[No Abstract] [Full Text] [Related]
11. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.
Kadoura S; Alhalabi M; Nattouf AH
Sci Rep; 2022 Mar; 12(1):4456. PubMed ID: 35292717
[TBL] [Abstract][Full Text] [Related]
12. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
13. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles.
Kuang Y; Hong Q; Chen Q; Lyu Q; Ai A; Fu Y; Shoham Z
Fertil Steril; 2014 Jan; 101(1):105-11. PubMed ID: 24161646
[TBL] [Abstract][Full Text] [Related]
14. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
Zhu X; Ye H; Fu Y
Fertil Steril; 2017 Sep; 108(3):505-512.e2. PubMed ID: 28697910
[TBL] [Abstract][Full Text] [Related]
15. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
Zhu X; Ye H; Fu Y
Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
[TBL] [Abstract][Full Text] [Related]
16. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
[TBL] [Abstract][Full Text] [Related]
17. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
18. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type.
Lambalk CB; Banga FR; Huirne JA; Toftager M; Pinborg A; Homburg R; van der Veen F; van Wely M
Hum Reprod Update; 2017 Sep; 23(5):560-579. PubMed ID: 28903472
[TBL] [Abstract][Full Text] [Related]
19. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol.
Huang TC; Huang MZ; Seow KM; Yang IJ; Pan SP; Chen MJ; Hwang JL; Chen SU
Sci Rep; 2021 Nov; 11(1):22732. PubMed ID: 34815477
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a progestin-primed ovarian stimulation protocol with a flexible GnRH antagonist protocol in patients with polycystic ovary syndrome who are participating in an IVF programme: study protocol for a randomised controlled trial.
Wang N; Zhu Q; Ma M; Liang Z; Tao Y; Wang Y; Kuang Y
BMJ Open; 2020 Dec; 10(12):e038153. PubMed ID: 33268401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
